Skip to main content
SpringerLink
Log in

Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

The Original Article was published on 11 January 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pappagallo M, Inturrisi C, Manfredi P. Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.” CNS Drugs. 2021. https://doi.org/10.1007/s40263-021-00891-0.

  2. Henter ID, Park LT, Zarate CAJ. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35:527–43. https://doi.org/10.1007/s40263-021-00816-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. US Drug Enforcement Administration. Drug and Chemical Information Section: Methadone. Springfield, VA, US Drug Enforcement Administration, Diversion, Control Division. 2019. https://www.deadiversion.usdoj.gov/drug_chem_info/methadone/methadone.pdf.

  4. Moryl N, Tamasdan C, Tarcatu D, Thaler HT, Correa D, Steingart R, et al. A phase I study of D-methadone in patients with chronic pain. J Opioid Manag. 2016;12:47–55.

    Article  Google Scholar 

  5. Hagler G. BioSpace: Relmada Therapeutics developing REL-1017 to treat major depression. April 21, 2020. 2020 [cited 2020. https://www.biospace.com/article/relmada-developing-rel-1017-to-treat-major-depression/. Accessed 21 Sept 2020.

  6. Relmada Therapeutics I. Relmada Therapeutics announces top-line results from REL-1017 Phase 2 study in individual with treatment resistant deprssion. October 15, 2019. 2019 [cited 2019. https://www.prnewswire.com/news-releases/relmada-therapeutics-announces-top-line-results-from-rel-1017-phase-2-study-in-individuals-with-treatment-resistant-depression-300938577.html. Accessed 21 Sept 2020.

Download references

Author information

Authors and Affiliations

  1. Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, NIMH-NIH, 10 Center Drive, Bldg 10 CRC, Unit 7 Southeast, Room 7-5342, Bethesda, MD, 20892, USA

    Ioline D. Henter, Lawrence T. Park & Carlos A. Zarate Jr.

Authors
  1. Ioline D. Henter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence T. Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos A. Zarate Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos A. Zarate Jr..

Ethics declarations

Funding

Funding for this work was provided by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIAMH002857). The work was completed as part of the authors’ official duties as Government employees. The views expressed do not necessarily reflect the views of the NIH, the Department of Health and Human Services, or the United States Government.

Conflict of interest

Dr. Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2R,6R)-hydroxynorketamine and (2S,6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.

Authors’ contributions

All authors contributed equally to the writing of this letter and approved the final version of the letter.

Availability of data and material

Not applicable.

Code availability

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Ethics approval

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henter, I.D., Park, L.T. & Zarate, C.A. Authors’ Reply to Pappagallo et al.: Comment on “Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status”. CNS Drugs 36, 205–206 (2022). https://doi.org/10.1007/s40263-021-00892-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-021-00892-z

Search

Navigation